Not Yet RecruitingNot Applicable

Prevalence of Helicobacter Pylori on Patients With Chronic Inflammatory Bowel Disease (IBD) at the CHU of Guadeloupe

Guadeloupe100 participantsStarted 2025-12-15

Plain-language summary

Clinical and experimental data suggest that dysbiosis may play a pivotal role in the pathogenesis of intestinal bowel disease (IBD). However, to the best of our knowledge, the composition of gastric and of intestinal microbiome has never been investigated in a population with IBD according to the presence/absence of Helicobacter pylori (H. pylori) in the stomach.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Patients over 18 years old Patients with IBD from the CHU of Guadeloupe Patients benefiting from an investigation of H. pylori infection through gastric biopsies and/or serology at the time of diagnosis of IBD Patients affiliated to the French social security system Free informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research) Exclusion Criteria: Patients of less than18 years Patients having not given their writing informed consent

What they're measuring

Prevalence of H. pylori infection in patients with Inflammatory Bowel Disease (IBD)

Timeframe: At the time of endoscopic evaluation (baseline only).

Trial details

NCT IDNCT07292454

SponsorCentre Hospitalier Universitaire de la Guadeloupe

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12-15

Contact for this trial

georgette Saint-Georges, MD

0590891445 georgette.saint-georges@chu-guadeloupe.fr

View on ClinicalTrials.gov More HELICOBACTER PYLORI INFECTIONS trials